Cutaneous leishmaniasis Skin and Connective Tissue Diseases Cutaneous leishmaniasis
Conditions
Interventions
Group 1 was treated with intramuscular 60 mg/kg/day glucantime (MA) and placebo for three weeks.
Group 2 was treated with intramuscular 30 mg/kg/day glucantime and 40 mg of the oral omeprazole for thr
Sponsors
Skin Diseases and Leishmaniasis Research Center (SDLRC) (Iran)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All of the patients had positive smear for leishman body and have not received any topical or systemic therapy for leishmaniasis. The age of patients was between 7-70 years old.
Exclusion criteria
Exclusion criteria: Patients who were pregnant or lactating and patients with history of cardiac, renal, hepatic diseases or patients with any contraindication for treatment were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Healing rate during the course of treatment was more in the groups treated with standard dose glucantime and placebo and low dose glucantime and omeprazole than the group treated with low dose glucantime and placebo (P <0.05). | — |
Secondary
| Measure | Time frame |
|---|---|
| Combination therapy with oral omeprazole and low dose of glucantime can be used as alternative treatment for leishmaniasis especially in patients with history of cardiac, renal, and hepatic disease. Patients with cardiac diseases were excluded because of some cardiac effects of the glucantime. However, glucantime is not absolutely contraindicated in patients with cardiac diseases and it can be prescribed with ECG monitoring. The study showed that the use of omeprazole as adjuvant therapy will decrease the dose of glucantime for the treatment of cutaneous leishmaniasis and therefore possibly decrease the risk of cardiac events attributed to the use of full dose of glucantime. | — |
Countries
Iran
Outcome results
None listed